Lifesci Capital Issues Positive Estimate for TARS Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Investment analysts at Lifesci Capital lifted their Q2 2026 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in a report issued on Tuesday, March 24th. Lifesci Capital analyst F. Brisebois now expects that the company will earn ($0.01) per share for the quarter, up from their prior forecast of ($0.36). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ FY2026 earnings at ($0.66) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The company had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million.

TARS has been the topic of a number of other reports. Guggenheim upped their price target on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $68.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $91.83.

Tarsus Pharmaceuticals Stock Up 0.4%

Tarsus Pharmaceuticals stock opened at $67.20 on Thursday. Tarsus Pharmaceuticals has a twelve month low of $38.51 and a twelve month high of $85.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. The firm has a market cap of $2.86 billion, a PE ratio of -41.48 and a beta of 0.55. The firm’s 50 day moving average price is $68.34 and its two-hundred day moving average price is $70.43.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. boosted its holdings in shares of Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after buying an additional 172 shares during the period. Seven Fleet Capital Management LP bought a new position in Tarsus Pharmaceuticals in the 4th quarter worth $368,000. Invesco Ltd. raised its holdings in Tarsus Pharmaceuticals by 8.0% in the 4th quarter. Invesco Ltd. now owns 1,012,357 shares of the company’s stock worth $82,892,000 after acquiring an additional 75,351 shares during the period. Mackenzie Financial Corp acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth $202,000. Finally, XTX Topco Ltd lifted its position in Tarsus Pharmaceuticals by 270.3% during the 4th quarter. XTX Topco Ltd now owns 18,410 shares of the company’s stock worth $1,507,000 after acquiring an additional 13,438 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 11,964 shares of the stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $801,588.00. Following the transaction, the chief executive officer owned 33,421 shares of the company’s stock, valued at approximately $2,239,207. This represents a 26.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Dianne C. Whitfield sold 4,174 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $279,658.00. Following the completion of the transaction, the insider directly owned 35,028 shares in the company, valued at $2,346,876. The trade was a 10.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 79,391 shares of company stock valued at $5,432,035. Corporate insiders own 8.97% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.